Clover Health Investments CLOV
NASDAQ CLOV
$4.76 -0.04 (-0.83%)
As of: Oct 21, 2026 · 10:41 AM EDT

Clover Health Investments (CLOV) Interest Coverage Ratio (2020 - 2023)

Updated

Clover Health Investments' Interest Coverage Ratio came in at -29332.71 for FY2023, compared with -215.05 in FY2022.

Analysis

Clover Health Investments (CLOV) Interest Coverage Ratio (2020 - 2023) Analysis & Trends

Going back to FY2019, Clover Health Investments' Interest Coverage Ratio data covers 5 years.

  • The FY2023 figure represents the lowest annual Interest Coverage Ratio in data going back to FY2019.
  • Per Business Quant, earlier years put Interest Coverage Ratio at -215.05 in FY2022, -199.50 in FY2021, -2.58 in FY2020 and -7.91 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Unitedhealth 377.58 Bn 256.15 Bn 36.67 Bn 8.31
2 Mckesson 120.82 Bn 104.71 Bn 3.69 Bn 17.13
3 Cvs Health 120.34 Bn 72.75 Bn 47.23 Bn 6.21
4 Elevance Health 94.17 Bn -47.71 Bn 13.45 Bn -96.39
5 Cigna 80.41 Bn 49.66 Bn 14.97 Bn -
6 Cencora 65.85 Bn 54.75 Bn 3.61 Bn -
7 Cardinal Health 60.99 Bn 44.83 Bn 2.56 Bn 9.23
8 Humana 51.67 Bn -36.20 Bn 5.50 Bn 6.90
9 Centene 34.65 Bn -55.70 Bn 14.55 Bn 7.83
10 Clover Health Investments 2.50 Bn 1.76 Bn 153.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 -4,126.00
Dec 31, 2022 -164.41
Sep 30, 2022 -183.41
Jun 30, 2022 -263.40
Mar 31, 2022 -217.07
Dec 31, 2021 -463.50
Sep 30, 2021 -369.44
Jun 30, 2021 -150.18
Mar 31, 2021 -101.35
Dec 31, 2020 -6.48
Sep 30, 2020 -2.33
Jun 30, 2020 2.73
Mar 31, 2020 -3.41
API Access

Clover Health Investments Interest Coverage Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-coverage-ratio&ticker=CLOV&period=max&api_key=YOUR_API_KEY